WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314211
Description: Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina.
MedKoo Cat#: 314211
Chemical Formula: C23H26ClN7O3
Exact Mass: 483.17857
Molecular Weight: 483.95064
Elemental Analysis: C, 57.08; H, 5.42; Cl, 7.33; N, 20.26; O, 9.92
Avanafil, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: TA-1790; TA 1790; TA1790; Avanafil; trade name: Stendra; Spedra
IUPAC/Chemical Name: (S)-4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2pyrimidinylmethyl)-5-pyrimidinecarboxamide
InChi Key: WEAJZXNPAWBCOA-INIZCTEOSA-N
InChi Code: InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
SMILES Code: O=C(C1=CN=C(N2[C@H](CO)CCC2)N=C1NCC3=CC=C(OC)C(Cl)=C3)NCC4=NC=CC=N4
The following data is based on the product molecular weight 483.95064 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Burke RM, Evans JD. Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag. 2012;8:517-23. doi: 10.2147/VHRM.S26712. Epub 2012 Aug 29. Review. PubMed PMID: 22973106; PubMed Central PMCID: PMC3433322.
2: Segal R, Burnett AL. Avanafil for the treatment of erectile dysfunction. Drugs Today (Barc). 2012 Jan;48(1):7-15. doi: 10.1358/dot.2012.48.1.1722068. Review. PubMed PMID: 22384456.
3: Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther. 2011;5:435-43. doi: 10.2147/DDDT.S15852. Epub 2011 Oct 18. Review. PubMed PMID: 22087063; PubMed Central PMCID: PMC3210072.
4: Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2010 Nov;19(11):1427-37. doi: 10.1517/13543784.2010.518955. Epub 2010 Oct 13. Review. PubMed PMID: 20939743.